Literature DB >> 18802924

Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD.

B Franke1, M Hoogman, A Arias Vasquez, J G A M Heister, P J Savelkoul, M Naber, H Scheffer, L A Kiemeney, C C Kan, J J S Kooij, J K Buitelaar.   

Abstract

ADHD is a neuropsychiatric disorder characterized by chronic hyperactivity, inattention and impulsivity, which affects about 5% of school-age children. ADHD persists into adulthood in at least 15% of cases. It is highly heritable and familial influences seem strongest for ADHD persisting into adulthood. However, most of the genetic research in ADHD has been carried out in children with the disorder. The gene that has received most attention in ADHD genetics is SLC6A3/DAT1 encoding the dopamine transporter. In the current study we attempted to replicate in adults with ADHD the reported association of a 10-6 SLC6A3-haplotype, formed by the 10-repeat allele of the variable number of tandem repeat (VNTR) polymorphism in the 3' untranslated region of the gene and the 6-repeat allele of the VNTR in intron 8 of the gene, with childhood ADHD. In addition, we wished to explore the role of a recently described VNTR in intron 3 of the gene. Two hundred sixteen patients and 528 controls were included in the study. We found a 9-6 SLC6A3-haplotype, rather than the 10-6 haplotype, to be associated with ADHD in adults. The intron 3 VNTR showed no association with adult ADHD. Our findings converge with earlier reports and suggest that age is an important factor to be taken into account when assessing the association of SLC6A3 with ADHD. If confirmed in other studies, the differential association of the gene with ADHD in children and in adults might imply that SLC6A3 plays a role in modulating the ADHD phenotype, rather than causing it. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802924     DOI: 10.1002/ajmg.b.30861

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  32 in total

1.  DAT1 and COMT effects on delay discounting and trait impulsivity in male adolescents with attention deficit/hyperactivity disorder and healthy controls.

Authors:  Yannis Paloyelis; Philip Asherson; Mitul A Mehta; Stephen V Faraone; Jonna Kuntsi
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

2.  Dopaminergic control of anxiety in young and aged zebrafish.

Authors:  Victoria Kacprzak; Neil A Patel; Elizabeth Riley; Lili Yu; Jing-Ruey J Yeh; Irina V Zhdanova
Journal:  Pharmacol Biochem Behav       Date:  2017-04-10       Impact factor: 3.533

3.  Genes of the dopaminergic system selectively modulate top-down but not bottom-up attention.

Authors:  Katja Kerstin Schneider; Andrea B Schote; Jobst Meyer; Christian Frings
Journal:  Cogn Affect Behav Neurosci       Date:  2015-03       Impact factor: 3.282

4.  Similar Subgroups Based on Cognitive Performance Parse Heterogeneity in Adults With ADHD and Healthy Controls.

Authors:  Jeanette C Mostert; Martine Hoogman; A Marten H Onnink; Daan van Rooij; Daniel von Rhein; Kimm J E van Hulzen; Janneke Dammers; Cornelis C Kan; Jan K Buitelaar; David G Norris; Barbara Franke
Journal:  J Atten Disord       Date:  2015-09-14       Impact factor: 3.256

5.  Dopamine transporter gene variation modulates activation of striatum in youth with ADHD.

Authors:  Anne-Claude Bédard; Kurt P Schulz; Edwin H Cook; Jin Fan; Suzanne M Clerkin; Iliyan Ivanov; Jeffrey M Halperin; Jeffrey H Newcorn
Journal:  Neuroimage       Date:  2009-12-21       Impact factor: 6.556

6.  Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: findings from a sample of adults.

Authors:  Lucas A de Azeredo; Diego L Rovaris; Nina R Mota; Evelise R Polina; Francine Z Marques; Verônica Contini; Eduardo S Vitola; Paulo Belmonte-de-Abreu; Luis A Rohde; Eugenio H Grevet; Claiton H D Bau
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-02-01       Impact factor: 5.270

7.  Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder.

Authors:  Joseph Biederman; Carter R Petty; Kristina S Ten Haagen; Jacqueline Small; Alysa E Doyle; Thomas Spencer; Eric Mick; Michael C Monuteaux; Jordan W Smoller; Stephen V Faraone
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

Review 8.  Molecular genetics of attention-deficit/hyperactivity disorder: an overview.

Authors:  Tobias Banaschewski; Katja Becker; Susann Scherag; Barbara Franke; David Coghill
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-02-10       Impact factor: 4.785

Review 9.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

10.  Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD.

Authors:  Barbara Franke; Alejandro Arias Vasquez; Stefan Johansson; Martine Hoogman; Jasmin Romanos; Andrea Boreatti-Hümmer; Monika Heine; Christian P Jacob; Klaus-Peter Lesch; Miguel Casas; Marta Ribasés; Rosa Bosch; Cristina Sánchez-Mora; Núria Gómez-Barros; Noèlia Fernàndez-Castillo; Mònica Bayés; Anne Halmøy; Helene Halleland; Elisabeth T Landaas; Ole B Fasmer; Per M Knappskog; Angelien J G A M Heister; Lambertus A Kiemeney; J J Sandra Kooij; A Marije Boonstra; Cees C Kan; Philip Asherson; Stephen V Faraone; Jan K Buitelaar; Jan Haavik; Bru Cormand; Josep Antoni Ramos-Quiroga; Andreas Reif
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.